Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.
glycation end products (AGEs) [1, 21 . AGE modified proteins increase slowly with ageing and are thought to contribute to normal tissue remodeling. Their level increases markedly in diabetic patients [3-5 as a result of sustained hyperglycemia, and lead to tissue damage through a variety of mechanisms including alteration of tissue proteins structure and function [1, 4] , stimulation of cellular responses [6] [7] [8] [9] [10] [11] [12] through AGE specific receptors [13] [14] [15] , or the generation of reactive oxygen intermediates [16] [17] [18] . However, the most dramatic rise in AGE levels is observed in uremia irrespective of the presence or absence of diabetes [3, 19, 20] . It is associated with a variety of disorders not only analogous to those observed in diabetes but also more specifically to end-stage renal failure such as dialysis-related amyloidosis [21, 22] . Interestingly, AGE accumulation in uremia is not related to hyperglycemia, therefore suggesting the presence in uremia of serum of unknown precursor(s) or catalyst(s) [20] .
Considerable evidence obtained in Vitro suggests that oxidative stress accelerates AGE formation [16, . Chronic uremia might be a state of increased oxidative stress, as suggested by increased lipid peroxidation assessed by malondialdehyde [28, 29] , an increased ratio of oxidized glutathione to reduced glutathione [30, 31] , a decreased activity of glutathione-dependent enzymes such as glutathione S-transferase, glutathione reductase and glutathione peroxidase [31] , and, more recently, elevated levels of "advanced oxidation protein products" [321. The possibility that oxidative stress contributed to elevated AGE levels in uremia was thus evaluated in the present study. AGEs include a variety of structures. We previously identified pentosidine [33] as a native structure for AGEs in dialysis-related amyloidosis [22] . We now extend this observation to N-(carboxymethyl)lysine (CML), another AGE structure reactive with anti-AGE antibody [34] . We further demonstrate that, in vitro, atmospheric oxygen taken as an oxidative stress accelerated, within a short incubation period, the production of pentosidine and CML from ascorbate but not from glucose. Finally, we report that in patients undergoing chronic HD the ratio of oxidized form of ascorbic acid to total ascorbate is increased, which is evidence taken to indicate an oxidative stress. Under those circumstances, there is a linear relationship between the plasma levels of oxidized ascorbate and those of both proteinlinked and free-form pentosidine. This relationship is absent in healthy individuals. This observation is taken as evidence that pentosidine and CML formation are enhanced by the oxidative stress of uremia and that, under these circumstances, oxidized ascorbate might be a precursor of both AGE structures.
Methods
Synthesis of CML and pentosidine To synthesize CML, a solution of 32 mmol of t-butyl bromoacetate in 10 ml of tetrahydrofuran was added dropwise to a stirred mixture of 26.7 mmol of N-t-hutoxycarbonyl-L-lysine methyl ester and 26.7 mmol of triethylamine in 400 ml of tetrahydrofuran.
The reaction mixture was stirred at room temperature for 15 hours, filtered to remove the precipitates, and concentrated in vacuo. The residue was then dissolved in ethyl acetate, washed with distilled water, concentrated in vacua, and further purified by silica gel column chromatography using 5/95 methanol/chloroform (vol/vol) to give N'°-t-hutoxycarbonyl-N-(carboxymethy1)-Llysine methyl ester. The obtained product (2.32 g) was hydrolyzed in 100 ml of 6 N HCI for three hours, lyophilized, and dissolved in distilled water. Pentosidine was prepared according to our previous method [20] . The identity of the final product was confirmed as CML and pentosidine by nuclear magnetic resonance and fast atom bombardment (FAB)-mass spectrometry (MS).
Sample preparation Human normal and acidic isoforms of /32-microglobulin (/32m) were purified from the urine of long-term HD patients who were free of urinary infection, as described previously [21] . A peptide (Ile-Gln-Arg-Thr-Pro-Gly-Ile, peptide-1), corresponding to the amino terminal seven amino acid residues except for glycine -6 instead of lysine-6, was synthesized by a peptide synthesizer model 432A (Applied BioSystems).
Purified normal l32m (50 xg) or the synthesized peptide (10 xg) was incubated under atmospheric oxygen at 37°C for several durations with various concentrations of either D-glucose (Wako Pure Chemicals, Tokyo, Japan) or ascorbic acid (AA; Wako Pure Chemicals), or both of them in 50 pA of 0.1 M sodium phosphate buffer (pH 7.4) containing 1 mvt diethylenetriaminepentaacetic acid (DTPA; Sigma Chemical Co., St. Louis, MO, USA). Upon incubation under atmospheric oxygen, AA is easily converted into its oxidized form, dehydroascorbic acid (DHA). In some experiments, incubation was performed in the presence of 40 mrvi sodium cyanoborohydride (NaBH1CN; Sigma), which reduces the Schiff base and prevents Amadori rearrangement, or in the presence of DHA (Sigma) instead of AA. After incubation, the samples underwent high-performance liquid chromatography (HPLC; model LC-1OA; Shimadzu, Kyoto, Japan) on a C18 reverse-phase column (Waters, Tokyo, Japan), and the /32m or peptide fraction was collected. To prepare /32m or bovine serum albumin (BSA) modified with pentosidine (pentosidine-/32m or -BSA) or CML (CML-132m or -BSA), synthesized pentosidine or CML were conjugated with f32m or BSA (essentially fatty acid-free grade; Sigma) according to our previous method [22] . Briefly, 2.0 mg of normal /32m or BSA was incubated with 4.3 xmol of CML or 4.3 .tmol of pentosidine in the presence of 0.03 mmol of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCI (Pierce) and 0.4 mg of N-hydroxysulfosuccinimide (Pierce) in 3 ml of phosphate buffered saline (PBS) for four hours at room temperature and then overnight at 4°C. BSA modified with pyrraline was kindly provided from Dr. Satoshi Miyata.
To examine pentosidine generation, 30 mg of human serum albumin (HSA; essentially fatty acid-free grade; Sigma) was incubated at 37°C with either 100 ifiM glucose, AA, or D-ribose (Sigma) in 1.0 ml of 0.1 M sodium phosphate buffer (pH 7.4) under atmospheric oxygen, and the level of pentosidine was determined at intervals by HPLC assay after acid hydrolysis as described below.
Immunoblot analysis
The samples (10 xg each) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 15% acrylamide gel for /32m and a 5 to 20% gradient gel for BSA.
After electrophoretical transfer to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA), the membrane was incubated with 3% skim milk overnight, and reacted for one hour at room temperature with anti-AGE mouse monoclonal IgG, 6D12 (10 xg/ml) [35] in the buffer containing 25 mM Tris-HCI (pH 7.5) and 0.5 M NaCI, followed by three-time washings with the same buffer containing 0.1% Tween-20. The membrane was then incubated with 1:3,000 diluted goat anti-mouse IgG conjugated with alkaline phosphatase (Organon Teknika) for one hour at room temperature, washed three times, and reacted with 5-bromo-4-chloro-3-indolyl phosphate (0.15 mg/mI) and nitroblue tetrazolium (0.30 mg/ml) solution (Gibco, Gaithersburg, MD, USA) in the buffer containing 0.1 M Tris-HC1 (pH 9.5), 0.1 M NaCl, 50 mM MgC12 until specific bands became clear. For competition experiments to confirm the specificity of immunostaining, the anti-AGE antibody was preincubated with 50 jxg of CML-BSA for three hours at 37°C and used for the experiments. Non-immune mouse IgG was used as a negative control.
Immunohistochemistty
Amyloid tissues were obtained at autopsy from patients with long-term HD patients who had undergone HD for more than ten years. The specimens were fixed in 10% formalin and embedded in paraffin. Specimens positive for Congo red staining were subjected to indirect immunohistochemical staining. In brief, sections cut at 2 jxm were mounted on slides coated with 3-aminopropyltriethoxy silane (Sigma), deparaffined, rehydrated in distilled water, and then incubated with Pronase (0.5 mg/ml; Dako, Glostrup, Denmark) in buffer containing 0,05 M Tris-HC1 (pH 7.2) and 0.1 M NaCI for 15 minutes at room temperature. The sections were washed with PBS containing 0.5% Tween and blocked in 4% skim milk for two hours. The sections were then incubated with either anti-AGE mouse monoclonal IgG (10 g/ml) or anti-f32m rabbit IgG (10 xg/ml; Dako, Glostrup, Denmark) overnight in humid chambers at room temperature. The sections were washed and incubated with 1:500 diluted goat anti-mouse or rabbit IgG conjugated with alkaline phosphatase (Dako) for two hours at room temperature, followed by the detection with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium solution. Competition experiments were performed using the anti-AGE antibody preincubated with CML-BSA. Non-immune mouse JgG was used as a negative control.
Fluorospectrometry
Protein-bound fluorescence was analyzed in a fluorescence spectrophotometer (model RF540; Shimadzu, Kyoto, Japan) at a protein concentration of 0.2 mg/mi in 10 mM sodium phosphate buffer (pH 7.2).
Protein digestion with endoproteinase Lys-C (Endo Lys-C)
To digest the sample into peptides for MS, normal 2m, glycated f32m, and CML-132m (100 sg each) were reacted with 5 xg of Endo Lys-C (Acromobacter Protease I; Wako Pure Chemicals) at 37°C for eight hours as described previously [36] . The digested peptides were separated on a HPLC system using a C18 reverse-phase column, detected by their absorbance at 214 nm, collected, and then subjected to MS and peptide sequencing on an automatic protein sequencer (model 473A gas-phase sequencer; Applied Biosystems, Foster City, CA, USA).
MS
A sector-type mass spectrometer JMS SX1O2A (JEOL, Akishima, Japan) was used for electrospray ionization (ES!) and fast atom bombardment (FAB) MS as described previously [361. of acetate. The plasma protein concentration was determined using a kit (Bio-Rad) with HSA as a standard. Plasma pentosidine is known to exist either in protein-linked form or in free-form [20] .
For quantitation of total pentosidine, plasma was lyophilized, hydrolyzed by 100 sl of 6 N HCI for 16 hours at 110°C under nitrogen, followed by neutralization with 100 1d of 5 N NaOH and 200 sl of 0.5 M sodium phosphate buffer (pH 7.4), filtered through a 0.5 m filter, and diluted with PBS. For quantitation of free pentosidine, the plasma was mixed with an equal volume of 10% TCA, centrifuged at 5000 x g for 10 minutes, filtered through a 0.5 xm filter, and diluted with PBS. Pentosidine in these specimens was quantitated by HPLC assay as described previously [201. Briefly, a 50 jsl solution of plasma acid hydrolysate (corresponding to 25 sg of plasma proteins) or diluted protein-free plasma (corresponding to 6.25 sl of plasma) was injected into an HPLC system and separated on a C18 reverse-phase column. The effluent was monitored at an excitation-emission wavelength of 335/385 nm using a fluorescence detector (RF-IOA; Shimadzu). Synthetic pentosidine was used to obtain a standard curve. The substance in the specimens, detected at the same retention time as authentic pentosidine, was confirmed as pentosidine by FAB-MS. The protein-linked pentosidine level was calculated as: proteinlinked pentosidine (pmol/mg) = [total pentosidine (pmol/ml)-free pentosidine (pmol/ml)]/protein concentration (mg/mi). Plasma protein-linked and free pentosidine levels were expressed as pmol per mg of protein and pmol per ml of plasma, respectively. Limits of detection were 0.05 pmol/mg for protein-linked pentosidine and 4 pmol/ml for free pentosidine.
Ascorbate measurement
The levels of AA and its oxidized form (oxiAA), that is, DI-IA and 2,3-diketogulonic acid, were measured in the same fresh plasma samples of HD patients described above and in 16 healthy individuals (10 males and 6 females, age range 28 to 61 years old), according to the method of Roe et a! [37] . Neither patients nor healthy controls were given ascorbate therapy. In this method, the level of total ascorbate (AA plus oxiAA) or oxiAA can be 120 ud of 30% HPO3, and 40 jxl of 0.1% dithiothreitol. These mixtures were kept on ice for 10 minutes and centrifuged at 15,000 >< g for 10 minutes. The supernatant (100 pA) was transferred to a well of a 96-well plate, mixed with 25 jsl of 2,4-dinitrophenylhydrazine, and incubated for three hours at 37°C. The mixture was then put on ice, added with 125 pA of 85% H2S04, and kept on ice for 10 minutes. The plate was kept for 30 minutes at room temperature and the absorbance at 540 nm was measured by a microplate leader (model 450; Bio-Rad). AA (Wako Pure Chemical) was used to obtain a standard curve.
Statistical analysis
Data are expressed as means sn. Student's t-test was used for a statistical evaluation of significant difference between the two groups. Correlation was assessed by linear regression analysis.
Results

Identification of CML as one of the AGE structures in amyloid fibrils
On immunoblot analysis (Fig. 1) , the anti-AGE mouse monoclonal antibody reacted with AGE-proteins prepared in vitro, such as AGE-132m (lane 3), AGE-BSA (lane 10), and AGE-keyhole limpet hemocyanin (KLH; data not shown), but not with their normal counterparts (lanes 1 and 9) nor Amadori compound (lane 2). When the immunoreactivity of this antibody was examined using several AGE structures postulated so far, the antibody recognized proteins modified with CML (lanes 5 and 12), but not with pentosidine (lanes 6 and 13) or pyrraline (lane 14) , indicating that the epitope structure of this antibody is CML. In fact, MALDITOF-MS of digested peptides generated by Endo Lys-C cleavage of 2m demonstrated carboxymethylation of the amino terminal peptide from AGE-/32m (Fig. 2C ) and CML-2m (Fig.  2D) , and both of which reacted with the antibody, whereas no carboxymethylation was detected in normal 132m ( Fig. 2A) , Amadori-/32m (Fig. 2B) (Fig. 3A) , indicating that these were /32m-amyloid deposits. The same deposits reacted with the monoclonal anti-AGE antibody (Fig. 3B) , in good agreement with our previous results [22] . Pre-adsorption of the anti-AGE antibody with CML-BSA ( Fig.   3C ) and AGE-BSA as well (data not shown) abolished the immunostaining. Non-immune mouse IgG gave no immunostaining pattern (data not shown).
Appearance of characteristic physicochemical properties of AGEs in /32m upon incubation with ascorbate When normal 132m was incubated for 7 or 21 days with AA or DHA in vitro under atmospheric oxygen, 2m turned brown and a major portion of 2m shifted its electrophoretic mobility on two-dimensional PAGE to an acidic position (data not shown) similar to that of acidic f32m, a major isoform of f32m recognized in amyloid fibrils as well as in 2m modified with AGEs [21] . In addition, incubation of f32m with ascorbate resulted in the formation of high-molecular-weight protein aggregates on SDS-PAGE (data not shown).
The protein-bound fluorescence of dialyzed materials from the reaction mixture was then analyzed by fluorospectrometer. Upon incubation with AA (Fig. 4 , line 5, 7 days; line 6, 21 days) or DHA (line 7, 7 days; line 8, 21 days), the /32m exhibited fluorescence spectra similar to those of acidic f32m (line 2) and normal f32m incubated with glucose for 42 days, that is, in vitro-prepared AGE-132m (line 4). The fluorescence peak exhibited an emission maximum at 430 to 450 nm upon excitation at 350 nm and an excitation maximum at 340 to 360 nm upon emission at 450 nm.
These findings indicate that incubation of normal /32m with ascorhate endows f32m with physicochemical properties of AGEs indistinguishable from those of acidic !32m or in vitro-prepared AGE-2m, that is, brown color, fluorescence, electrophoretical shift to an acidic position, and polymerization tendency.
Formation of CML and pentosidine in /32m upon incubation with ascorbate
When f32m was incubated with glucose and analyzed by ES I-MS (Fig. 5B) , a significant peak (AM) was detected in addition to a peak (N) corresponding to normal f32m (Fig. 5A) . The difference in the molecular mass from peak N to peak AM was exactly 164 Da, indicating that this peak corresponds to the /32m with one Amadori product [N-( 1-deoxyfructosyl)group]. However, no peak corresponding to the 132m with CML (an increase of 58 Da in the molecular mass) was detected in the ESI mass spectrum. By contrast, when 2m was incubated with AA ( Fig. 5C ) and DHA (data not shown), a peak of carboxymethylated /32m (peak CML) appeared in the ESI mass spectrum. When /32m was incubated for 15 hours with glucose and AA, both peak AM and CML were identified in the mass spectrum (Fig. 5D ). Changing the ratio of (data not shown). Both glucose and AA are capable of forming a covalent adduct with this peptide in a concentration-dependent manner, leading to addition of an adduct of 164 Da and 58 Da, respectively (Figs. 6 A, B) . When peptide-1 was incubated simultaneously with glucose and AA, both peak AM and CML were identified in the mass spectrum (Fig. 6C) . Changing the ratio of glucose and AA concentrations resulted in a correlative change of the ratio between the two peaks (Fig. oD) . The contention that ascorbate initiates the glycoxidation reaction with proteins and forms CML was further supported by the result of Western blot analysis (Fig. 1 ). Upon incubation with AA under atmospheric oxygen, both 2m (lane 4) and BSA (lane 11) reacted with the monoclonal anti-AGE antibody.
To know whether pentosidine, another AGE structure in amyloid fibrils of patients with dialysis-related amyloidosis [22] , is also formed in the presence of ascorbate, HSA was incubated with either ribose, glucose, or AA, and the amount of pentosidine generated was determined by HPLC assay (Fig. 7) . Upon incubation with ribose, a well-known source of pentosidine, HSA formed brown aggregates for a short duration, indicating accelerated pentosidine formation. Although both glucose and AA could be a source of pentosidine, the rate of pentosidine formation with AA (47.6 pmol!mg of HSAJweek in this condition) is about ten times faster than that with glucose (4.8 prnol/mg!week).
Increased ascorbate oxidation in HD patients
Plasma ascorbate level was measured in non-diabetic HD patients. Total ascorbate levels were markedly lower (P < 0.0001) in HD patients (4.51 2.84 jig/mI) than in normal individuals (10.23 3.09 jig/mI), in good agreement with a previous report [28] . By contrast, the ratio of oxiAA to total ascorbate, was much higher (P < 0.0001) in HD patients (0.87 0.16) than that in normal subjects (0.35 0.11; Fig. 8A ). If the ratio of oxiAA to total ascorhate is taken as a marker of the redox state, this finding indicates a significantly higher oxidative stress in HD patients than in normal subjects.
OxiAA is one of the reactive species for the Maillard reaction with AA [24, 25, [38] [39] [40] . Interestingly, its serum level in HD patients is significantly correlated with protein-linked pentosidine (P < 0.01) and with free-form pentosidine (P < 0.05; Fig. 8B ). No such correlation is observed in normal subjects despite a similar range of oxiAA serum levels.
Discussion
In the first part of this paper, we demonstrate that CML is a native structure of AGEs in f32ni amyloid deposits of patients on HD. This observation, taken together with our recent identification of pentosidine in similar dialysis-related amyloidosis deposits [22] , establishes the variety of molecular structures developed as a result of advanced glycation in uremia. Both epitopes have also been recognized in the skin collagen of non-uremic diabetic patients [5] . Recognition of such specific molecular motives in amyloid deposits should help unravel the mechanisms of dialysisrelated amyloidosis. Both pentosidine and CML are useful biomarkers of the cumulative protein damage induced by glycoxidation [16, 25] . Their presence in amyloid fibrils suggests a potential link between oxidative stress and the development of dialysisrelated amyloidosis.
Simultaneously, we demonstrate that the monoclonal anti-AGE antibody [35] utilized in this and in a previous study [21] , recognizes only CML, but neither pentosidine nor pyralline, which are other AGE structures. Reddy et al [34] also found recently that the major epitope of their polyclonal anti-AGE antibody was CML. Our own polyclonal anti-AGE antibody raised by immunization with AGE-KLH reacted with proteins (BSA, 2m, and KLH) modified with CML, but not with their counterparts modified with pentosidine nor pyrraline (our unpublished observation). These findings support the assumption by Baynes and colleagues that AGEs are largely glycoxidation products, and that CML is a major antigenic determinant in AGE-proteins. In fact, the amount of CML was shown to be approximately 40 to 70 times higher than that of pentosidine in skin collagen of diabetic patients [5] .
AGE accumulation is enhanced in diabetes as a result of sustained hyperglycemia. In uremia by contrast, despite an even more striking rise in the serum levels of AGEs including pentosidine, glucose levels are normal. We, therefore, postulated the existence in uremia of factors either producing unknown precursor(s) or catalyzing the formation of AGEs. In the second part of this work, we now provide evidence suggesting that AGE accumulation including pentosidine and CML is linked in uremia to a redox imbalance.
The formation of advanced glycoxidation products has been closely linked to oxidation processes. Wolff et al demonstrated that reducing sugars can autoxidize by metal-catalyzed oxidative processes and generate H202, reactive oxygen intermediates, and ketoaldehydes, which contribute to chromo-and fluorophoric alterations of proteins [26, 27] . Ahmed, Thorpe and Baynes showed that CML is formed on oxidative degradation of fructoselysine [23] and also by reaction with autoxidative products of Oxidized form of ascorbate, ji g/ml ascorbate [241 and glucose [41] . They further demonstrated that oxidation is an essential process in the formation of pentosidine [25] . These findings indicate that AGEs are products of the combined processes of glycation and oxidation.
The hypothesis that an increased oxidative stress contributes to the generation of AGEs in uremia is supported by both our in vitro and in vivo observations. In vitro, the incubation of 132m or HSA with ascorbate, under oxidative stress of atmospheric oxygen, leads to the accelerated formation of AGEs, and more specifically CML and pentosidine, whether or not glucose is present in the medium. The appearance of AGEs in the medium was established first by the detection within 7 to 21 days of !32m modifications indistinguishable from those of acidic and in vitro-prepared AGEf32m, that is, brown color, fluorescence, electrophoretical shift to an acidic position and polymerization tendency, and second by a specific recognition by a monoclonal anti-AGE antibody. A more detailed analysis by ESI-MS reveals the prompt appearance, within 15 hours, of the specific AGE structure, CML. CML formation was further located mainly to the amino terminal seven amino acid residue of 132m; when this synthesized peptide was incubated under the same condition as whole 2m, CML was detected by FAB mass spectra within the same time span.
Pentosidine also was generated at an accelerated rate as demonstrated by the incubation of HSA under similar conditions. AGE production was markedly accelerated under oxidative stress only in the presence of ascorbate, a reducing substance, precursor of both pentosidine and CML [24, 25, 40] . Neither CML nor pentosidine generation was accelerated when only glucose was present in the incubation medium. These observations suggest that the oxidative stress contributes to AGE formation only in the presence of precursors. This conclusion is further supported by in vitro evidence that the absence of oxygen in the incubation medium prevents the ascorbate-induced enhancement of CML and pentosidine production [23, 25] . In vivo observations provide further insights into the generation of AGEs in uremic subjects. The ratio of oxiAA to total ascorbate is markedly increased above normal in patients given chronic HD, suggesting that uremia is associated with increased oxidative stress. The existence of a redox imbalance in chronic uremia is supported by several lines of evidence such as an increased lipid peroxidation [28, 29] , an increased ratio of oxidized to reduced glutathione [30, 31] , a decreased activity of glutathione-dependent enzymes [31] , and, more recently, an elevated level of "advanced oxidation protein products" [32] .
However, the most interesting result of the in vivo observations is the demonstration of a correlation between the plasma concentration of oxiAA and both protein-linked and free levels of pentosidine. The plasma levels of oxiAA in our patients are within the normal range (0.36 2.84 vs. 0.34 0.12 jxglml in normals) as a result of both a reduced concentration of total ascorbate, a well known feature of chronic uremia [28] and the augmented oxiAA/total AA ratio. This correlation, absent in normal subjects, suggests that oxiAA level is a rate limiting precursor of AGEs, in this case pentosidine, only under conditions of oxidative stress. Of note, Dyer et al [25] raised this hypothesis on the basis of in vitro studies.
Witko-Sarsat et al [32] have recently described a similar relationship between the serum levels of pentosidine and "advanced oxidation protein products" (taken as highly oxidized proteins) in normal subjects and HD patients. These results were interpreted as evidence that both "advanced oxidation protein products" and pentosidine levels are determined by the intensity of the prevailing oxidative stress. The oxiAA-pentosidine relationship observed in our HD patients does not fit this hypothesis as we found no correlation between the intensity of the oxidative stress, assessed by the ratio of oxiAA to total ascorbate, and pentosidine. This tentative conclusion will need confirmation by other methods evaluating the severity of the oxidative stress. [43] and their BSA conjugates, exhibit no ligand activity for the AGE receptor of peritoneal macrophage [35, 44] , these data demonstrate that another, as yet unidentified, AGE structure is responsible for the biological activity towards monocytes/macrophages [6-I 0, 14, 15] . If the same factors govern the production of the various AGE structures, CML and pentosidine might prove adequate surrogate markers for this biologically active AGE structure.
To summarize, our results have identified both CML and pentosidine as specific AGE structures present in dialysis-related amyloid deposits. They further suggest that, in uremia, CML and pentosidine production is determined both by an increased oxidative stress and the availability of precursors among which oxiAA and ribose have been identified.
